MGST2 was significantly downregulated after the treatment with a nanozymatic system in CT26 (colon carcinoma) and MKN45 (human gastric adenocarcinoma) cells, as well as in a tumor-bearing mice model [45]. The gene discussed is MGST2; the disease is neoplasm.